Intellia Therapeutics (NTLA) AI Stock Analysis

• Market Cap: $1.26B
• Dividend Yield: N/A
• Average Volume (3M): 5.64M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.48
• Revenue Growth: -13.37%
• EPS Growth: 2.57%
• Country: US
• Employees: 403
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -1.10
• Shares Outstanding: 103,583,400
• 10 Day Avg. Volume: 4,245,128
• 30 Day Avg. Volume: 5,635,424
• PEG Ratio: -4.30
• Price to Book (P/B): 1.10
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.25
• Enterprise Value/Market Cap: 0.68
• Enterprise Value/Revenue: 4.42
• Enterprise Value/Gross Profit: 21.04
• Enterprise Value/Ebitda: -0.41
• 1Y Price Target: $28.19
• Price Target Upside: 144.28% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 23

• Rating: 60 Neutral
• Price Target: $12.50 ▲(8.32%Upside)

Intellia Therapeutics' overall score reflects a mix of significant clinical progress and financial challenges typical of early-stage biotech firms. The primary strengths lie in its advanced clinical pipeline and strong balance sheet, while financial performance and valuation concerns due to ongoing losses weigh down the score. Technical momentum provides a positive short-term outlook, balanced by the risks associated with developmental stage investments.

Positive Factors

Clinical Trial Progress

The Phase 3 HAELO study completed screening and is no longer recruiting, indicating strong physician/patient interest.

Efficacy

All patients are currently attack-free and long-term prophylaxis-free for a median of 23 months, highlighting the treatment's effectiveness.

Safety Profile

Safety remains clean with no treatment-emergent serious adverse events, supporting Lonvo-z’s best-in-class efficacy profile.

Negative Factors

Market Limitations

The HAE market and available treatments limit Lonvo-z opportunity size, suggesting limited uptake.

Market Opportunity

The valuation disconnect between the HAE opportunity and NTLA’s market cap is one of the widest, which may persist until NTLA releases pivotal HAE data or addresses investor concerns on the balance sheet.

Replicability Concerns

The potential for a larger sample size in Phase II to lead to an inferior effect compared to Phase I results suggests uncertainty in replicating earlier success.

Intellia Therapeutics Business Overview & Revenue Model

Company Description

Intellia Therapeutics (NTLA) is a biotechnology company that focuses on developing novel therapeutics using CRISPR/Cas9 gene-editing technology. The company is engaged in the research and development of treatments aimed at addressing genetic disorders. Intellia's core products include various therapeutic candidates targeting diseases such as transthyretin amyloidosis and hereditary angioedema, among others. The company operates primarily within the healthcare and biotechnology sectors.

How the Company Makes Money

Intellia Therapeutics generates revenue through a combination of collaborations, strategic partnerships, and the development of its proprietary gene-editing therapies. The company enters into agreements with other pharmaceutical companies and research institutions to co-develop and commercialize CRISPR-based therapies, which often involve upfront payments, milestone payments, and royalties on product sales. Additionally, Intellia invests in its pipeline of therapeutic candidates, driving long-term revenue potential through the successful development and eventual commercialization of these products. Strategic partnerships play a significant role in the company's earnings, providing both financial support and shared expertise to advance its gene-editing technology.

Intellia Therapeutics Financial Statement Overview

Summary

Intellia Therapeutics is experiencing typical financial challenges for a biotech company in a growth phase, with high R&D expenses leading to net losses and negative cash flows. Despite a strong cash position, the decline in revenue and shareholder equity indicates financial instability.

Income Statement

Intellia Therapeutics has faced a challenging financial environment, with declining revenues from $57.99 million in 2020 to $36.27 million in 2023, and ultimately to zero in 2024. The company has consistently incurred net losses, with a significant net loss of $519.02 million in 2024, indicating high operational costs and low revenue, characteristic of a biotech firm in early stages of development.

Balance Sheet

The balance sheet shows adequate cash reserves with $601.52 million in cash and equivalents. However, the debt-to-equity ratio stands at 0.24, indicating manageable leverage, but the persistent decrease in stockholders' equity from $1.05 billion in 2023 to $871.96 million in 2024 suggests a deterioration in shareholder value. The equity ratio is relatively stable, providing a moderate level of financial stability.

Cash Flow

The cash flow statement highlights negative free cash flow each year, with a free cash flow of -$408.07 million in 2024, driven by high operating cash outflows. The operating cash flow to net income ratio is unfavorable due to consistent losses, signaling inefficiencies in cash generation relative to expenses. This is typical for a biotech firm still in development phases.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	45.57M	57.88M	36.27M	52.12M	33.05M	57.99M
Gross Profit	40.40M	47.59M	27.30M	44.55M	26.16M	-92.41M
EBITDA	-530.80M	-523.98M	-506.31M	-450.59M	-260.96M	-130.27M
Net Income	-525.91M	-519.02M	-481.19M	-490.21M	-259.72M	-125.57M
Balance Sheet
Total Assets	344.36M	1.19B	1.30B	1.52B	1.29B	676.32M
Cash, Cash Equivalents and Short-Term Investments	296.58M	601.51M	912.22M	1.26B	1.09B	597.37M
Total Debt	19.51M	210.20M	115.35M	130.70M	74.02M	39.30M
Total Liabilities	80.03M	319.06M	250.81M	284.53M	254.22M	149.25M
Stockholders Equity	264.34M	871.96M	1.05B	1.24B	1.04B	527.07M
Cash Flow
Free Cash Flow	-381.15M	-354.66M	-408.07M	-391.68M	-237.79M	-53.50M
Operating Cash Flow	-377.15M	-348.88M	-394.09M	-333.29M	-225.03M	-49.91M
Investing Cash Flow	213.99M	125.57M	-31.35M	160.31M	-550.78M	-214.49M
Financing Cash Flow	125.75M	185.75M	130.32M	582.96M	736.69M	371.78M

Intellia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.54
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTLA, the sentiment is Positive. The current price of 11.54 is above the 20-day moving average (MA) of 9.97, above the 50-day MA of 8.99, and below the 200-day MA of 11.64, indicating a neutral trend. The MACD of 0.82 indicates Negative momentum. The RSI at 66.02 is Neutral, neither overbought nor oversold. The STOCH value of 89.10 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NTLA.

Intellia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTLA	60 Neutral	$1.26B	―	-57.92%	―	-13.37%	2.57%
Sector *	59 Neutral	HK$15.49B	5.53	-7.44%	4.08%	11.55%	-28.15%
ARVN	56 Neutral	$600.72M	―	-35.41%	―	―	―
VIR	56 Neutral	$819.75M	―	-44.59%	―	-73.79%	-5.24%
NRIX	56 Neutral	$968.61M	―	-50.67%	―	41.86%	10.48%
XNCR	51 Neutral	$664.02M	―	-33.48%	―	-25.88%	-29.16%
RCKT	40 Underperform	$340.45M	―	-60.45%	―	―	6.99%

Intellia Therapeutics Corporate Events

Intellia Therapeutics Announces Positive Phase 1 Trial Data

On June 15, 2025, Intellia Therapeutics announced positive three-year data from the Phase 1 trial of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress. The trial showed a 98% mean reduction in monthly HAE attack rates with a single dose, and the treatment was well-tolerated with no serious adverse events. The ongoing global Phase 3 HAELO trial has completed screening ahead of schedule, and Intellia plans to present further data in 2025, with a U.S. launch expected in 2027, pending FDA approval.

The most recent analyst rating on (NTLA) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Intellia Therapeutics Holds Annual Stockholders’ Meeting

On June 11, 2025, Intellia Therapeutics held its annual stockholders’ meeting, where several key decisions were made. The stockholders approved the 2025 Equity Incentive Plan, elected three directors for a three-year term, ratified Deloitte & Touche LLP as the independent auditor for 2025, and decided on an annual frequency for advisory votes on executive compensation. These decisions are expected to impact the company’s governance and operational strategies.

The most recent analyst rating on (NTLA) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Intellia Therapeutics Updates on Phase 3 Study Progress

On May 28, 2025, Intellia Therapeutics provided a business update on its Phase 3 studies. The HAELO study for NTLA-2002 in hereditary angioedema and the MAGNITUDE-2 study for nex-z in ATTRv-PN are progressing well, with anticipated U.S. commercial launches in 2027 and 2029, respectively. The MAGNITUDE study for ATTR-CM is also on track, with over 200 patients dosed and expected enrollment completion by early 2027. Adverse events reported in the MAGNITUDE study have been consistent with earlier phases, with one recent case of asymptomatic liver transaminase elevations resolving without intervention.

The most recent analyst rating on (NTLA) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Intellia Therapeutics Reports Positive Phase 1 Trial Results

On May 18, 2025, Intellia Therapeutics announced positive two-year follow-up data from its ongoing Phase 1 trial of nexiguran ziclumeran (nex-z) for hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). The study showed a significant reduction in serum TTR levels and clinically meaningful improvements in neuropathic impairment measures, with no serious adverse events, indicating potential for nex-z as a one-time treatment. The results were presented at the Peripheral Nerve Society Annual Meeting, highlighting the drug’s potential to improve outcomes for patients who previously showed disease progression on patisiran.

The most recent analyst rating on (NTLA) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.